| 000 | 01754 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516164027.0 | ||
| 264 | 0 | _c20131115 | |
| 008 | 201311s 0 0 eng d | ||
| 022 | _a1532-1827 | ||
| 024 | 7 |
_a10.1038/bjc.2013.474 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBowles, D W | |
| 245 | 0 | 0 |
_aA multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cSep 2013 |
||
| 300 |
_a1085-92 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xblood |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDocetaxel |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGonanes _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
| 650 | 0 | 4 |
_aTaxoids _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMa, W W | |
| 700 | 1 | _aSenzer, N | |
| 700 | 1 | _aBrahmer, J R | |
| 700 | 1 | _aAdjei, A A | |
| 700 | 1 | _aDavies, M | |
| 700 | 1 | _aLazar, A J | |
| 700 | 1 | _aVo, A | |
| 700 | 1 | _aPeterson, S | |
| 700 | 1 | _aWalker, L | |
| 700 | 1 | _aHausman, D | |
| 700 | 1 | _aRudin, C M | |
| 700 | 1 | _aJimeno, A | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 109 _gno. 5 _gp. 1085-92 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/bjc.2013.474 _zAvailable from publisher's website |
| 999 |
_c23001140 _d23001140 |
||